Federated Hermes’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-3
| Closed | -$71 | – | 2174 |
|
|
2023
Q4 | $71 | Buy |
+3
| New | +$53 | ﹤0.01% | 2031 |
|
|
2022
Q1 | – | Sell |
-77,403
| Closed | -$262K | – | 2360 |
|
|
2021
Q4 | $262K | Buy |
77,403
+77,361
| +184,193% | +$294K | ﹤0.01% | 1600 |
|
|
2021
Q3 | $1K | Sell |
42
-481
| -92% | -$1.9K | ﹤0.01% | 2177 |
|
|
2021
Q2 | $2K | Sell |
523
-306
| -37% | -$1.36K | ﹤0.01% | 2106 |
|
|
2021
Q1 | $4K | Buy |
829
+504
| +155% | +$2.71K | ﹤0.01% | 2085 |
|
|
2020
Q4 | $2K | Sell |
325
-24
| -7% | -$182 | ﹤0.01% | 2139 |
|
|
2020
Q3 | $3K | Sell |
349
-168
| -32% | -$898 | ﹤0.01% | 2082 |
|
|
2020
Q2 | $2K | Sell |
517
-124,522
| -100% | -$359K | ﹤0.01% | 2107 |
|
|
2020
Q1 | $185K | Buy |
125,039
+26,451
| +27% | +$44.4K | ﹤0.01% | 1586 |
|
|
2019
Q4 | $193K | Buy |
98,588
+62,185
| +171% | +$234K | ﹤0.01% | 1609 |
|
|
2019
Q3 | $186K | Buy |
36,403
+33,088
| +998% | +$200K | ﹤0.01% | 1596 |
|
|
2019
Q2 | $24K | Buy |
3,315
+2,883
| +667% | +$32.6K | ﹤0.01% | 1778 |
|
|
2019
Q1 | $6K | Buy |
+432
| New | +$4.59K | ﹤0.01% | 1959 |
|
|
2018
Q2 | – | Sell |
-172
| Closed | -$2K | – | 2289 |
|
|
2018
Q1 | $2K | Buy |
+172
| New | +$2.14K | ﹤0.01% | 2075 |
|
|
2017
Q3 | – | Sell |
-2,393
| Closed | -$14K | – | 2206 |
|
|
2017
Q2 | $14K | Buy |
2,393
+272
| +13% | +$1.16K | ﹤0.01% | 1793 |
|
|
2017
Q1 | $9K | Buy |
+2,121
| New | +$6.08K | ﹤0.01% | 1842 |
|
Other funds holding CBAY
Federated Hermes's CBAY Position: Q1 2024 in Review
Federated Hermes sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 3 shares — an estimated $71 sold.
Federated Hermes first reported a position in CBAY in Q1 2017 and held it in 16 quarters. The position peaked at $262K in Q4 2021. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- Federated Hermes reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- Federated Hermes sold 3 Cymabay Therapeutics shares in Q1 2024, an estimated $71.
- Federated Hermes first reported a position in Cymabay Therapeutics in Q1 2017 and held it in 16 quarters.
- Federated Hermes's Cymabay Therapeutics position peaked at $262K in Q4 2021.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on Federated Hermes's 13F filing for Q1 2024, filed 14 May 2024.